What does the evidence say about Pomegranate Blood Flow Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Pomegranate Blood Flow Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Conclusion Under tightly controlled dietary conditions, a single dose of pomegranate extract did not reduce post-OCC TMAO responses in the overall cohort. [Haarhuis JE (2026); evidence level 2] - Introduction Polyphenol-rich pomegranate extract has been shown to inhibit microbial trimethylamine (TMA) production from L-carnitine. [Haarhuis JE (2026); evidence level 2] - Previous clinical studies have examined effects of polyphenol-rich interventions on fasting trimethylamine N-oxide (TMAO) concentrations but have not assessed pharmacokinetic TMAO responses following an oral carnitine challenge (OCC). [Haarhuis JE (2026); evidence level 2] - PSO significantly reduced histological injury: Median total injury score was 9 (7-11) in IR, 6 (4-8) in IR + PSO low, and 3 (2-5) in IR + PSO high ( P < 0.001). [Altimimi MLM (2026); evidence level 4] - Multivariable logistic regression showed that PSO treatment was associated with lower odds of severe IR injury (odds ratio: 0.40, 95% confidence interval: 0.18-0.90). [Altimimi MLM (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.